Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv)

A compound according to the chemical structure:

• Where W is N—RWNa, O, S, or CRaRb;
• X is N or C;
• Y is N—RYNa, O, S or CRaRb;
• Z is N—RZNa, O, S, or CRaRb;
• with the proviso that W, Y and Z are not simultaneously CRaRb;
• RWNa is absent, H or an optionally substituted C1-C3 alkyl;
• RYNa is absent, H or an optionally substituted C1-C3 alkyl;
• RZNa is absent, H or an optionally substituted C1-C3 alkyl;
• Each Ra is independently absent, H, or an optionally substituted C1-C3 alkyl;
• Each Rb is independently H, CN, or an optionally substituted C1-C3 alkyl;
• Xa is N—RNXa, CRbaRba, O or S;
• RNXa is H or an optionally substituted C1-C3 alkyl group;
• Each Rba is independently H or an optionally substituted C1-C3 alkyl;
• Xb is N, C—RXba;
• O or S;
• RXb is absent, H, or an optionally substituted C1-C3 alkyl;
• RXBa is H, or an optionally substituted C1-C3 alkyl;
• R1 is an optionally substituted carbocyclic or heterocyclic group;
• and
• R2 is an optionally substituted carbocyclic or heterocyclic group;
• or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph, thereof.